Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy ...

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Bharat Biotech launches Nucelion Therapeutics, a CRDMO focused on advanced cell and gene therapies for global life science innovators.

Bharat Biotech launches Nucelion Therapeutics, a CRDMO in Hyderabad for advanced cell and gene therapy manufacturing and development.

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Bharat Biotech launches Nucelion, the next-gen cell and gene therapy, CRDMO: Our Bureau, Bengaluru Monday, November 3, 2025, 17:30 Hrs [IST] Nucelion Therapeutics, a newly establi ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.